Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Net Cash Flow (2016 - 2025)

Sunshine Biopharma's Net Cash Flow history spans 14 years, with the latest figure at -$941715.0 for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 50.04% year-over-year to -$941715.0; the TTM value through Dec 2025 reached -$1.4 million, up 74.49%, while the annual FY2025 figure was -$1.4 million, 74.49% up from the prior year.
  • Net Cash Flow reached -$941715.0 in Q4 2025 per SBFM's latest filing, down from -$770559.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $28.5 million in Q2 2022 to a low of -$19.0 million in Q4 2022.
  • Average Net Cash Flow over 5 years is $384287.0, with a median of -$418886.5 recorded in 2021.
  • Peak YoY movement for Net Cash Flow: skyrocketed 41959.55% in 2022, then crashed 25270.25% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$335777.0 in 2021, then tumbled by 5547.28% to -$19.0 million in 2022, then skyrocketed by 84.23% to -$3.0 million in 2023, then soared by 36.95% to -$1.9 million in 2024, then surged by 50.04% to -$941715.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Net Cash Flow are -$941715.0 (Q4 2025), -$770559.0 (Q3 2025), and $1.8 million (Q2 2025).